Stay updated with breaking news from Boxed Warning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Gottfried E. Konecny, MD, discusses the FDA approval of mirvetuximab soravtansine for patients with FRα-positive, platinum-resistant ovarian cancer.
OPSYNVI® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to...
The approval marks the first and only once-daily single-tablet combination therapy for patients with pulmonary arterial hypertension.
/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results...
Randomized Phase 2 study met the primary endpoint in patents with hidradenitis suppurativa , reinforcing efficacy and safety profile of ruxolitinib cream Results presented as a late-breaking...